These Analysts Increase Their Forecasts On Abbott Following Better-Than-Expected Q2 Results

The important signal is not the beat itself; it is that ABT is turning mid-single-digit comparable growth into higher EPS without needing a big estimate reset. That usually implies operating leverage and pricing/mix discipline, which is exactly the sort of quality dividend-grower setup that can support a higher multiple over time. The limitation is that the updated earnings range still sits close to consensus, so there is less immediate upside to numbers than the headline suggests.

Relative winners are the recurring-revenue, consumables-heavy medtech names; the losers are slower growers that trade on “defensive” status alone. ABT’s execution raises the bar for names like MDT and ZBH, where investors need proof of organic acceleration to defend valuation. In diabetes care and diagnostics, sustained strength also pressures pure-play rivals such as DXCM and TNDM on pricing and share capture, because ABT can afford to compete more aggressively with a broader product portfolio.

The main risk is that this is a clean quarter against easy comps rather than a durable second-half inflection. Over the next 1-3 months, watch whether comparable sales hold above ~5% and whether margins keep expanding; if not, the stock likely reverts to a range trade. Over 6-18 months, the bull case is that ABT compounds earnings high-single to low-double digits with less volatility than most peers, but near-term upside is probably more modest than the analyst target raises imply.

The contrarian view is that consensus may be underestimating ABT’s ability to self-fund growth and capital returns without M&A, but the market may also be right that much of the good news is already in the tape. This looks more like a quality confirmation than a full re-rating event.